Oramed Pharmaceuticals (NASDAQ:ORMP) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Oramed Pharmaceuticals (NASDAQ:ORMP) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02, Zacks reports.

Oramed Pharmaceuticals Price Performance

NASDAQ ORMP traded down $0.04 on Friday, reaching $3.28. The company had a trading volume of 42,175 shares, compared to its average volume of 208,981. Oramed Pharmaceuticals has a 1 year low of $1.82 and a 1 year high of $3.76. The firm has a 50-day moving average of $3.41 and a 200-day moving average of $2.91. The firm has a market capitalization of $130.55 million, a PE ratio of 2.62 and a beta of 1.31.

Oramed Pharmaceuticals Announces Dividend

The business also recently announced a dividend, which was paid on Monday, January 26th. Stockholders of record on Friday, January 16th were paid a $0.25 dividend. The ex-dividend date was Friday, January 16th. Oramed Pharmaceuticals’s dividend payout ratio (DPR) is 19.84%.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Oramed Pharmaceuticals in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock presently has an average rating of “Hold”.

Institutional Investors Weigh In On Oramed Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in ORMP. XTX Topco Ltd lifted its holdings in Oramed Pharmaceuticals by 59.9% in the 4th quarter. XTX Topco Ltd now owns 38,182 shares of the biotechnology company’s stock worth $109,000 after buying an additional 14,297 shares in the last quarter. Quadrature Capital Ltd acquired a new stake in shares of Oramed Pharmaceuticals during the fourth quarter worth $119,000. HRT Financial LP bought a new position in shares of Oramed Pharmaceuticals in the 4th quarter worth about $131,000. Jane Street Group LLC boosted its holdings in shares of Oramed Pharmaceuticals by 35.3% in the 1st quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company’s stock valued at $144,000 after buying an additional 17,510 shares during the period. Finally, Squarepoint Ops LLC boosted its holdings in shares of Oramed Pharmaceuticals by 95.1% in the 4th quarter. Squarepoint Ops LLC now owns 58,272 shares of the biotechnology company’s stock valued at $166,000 after buying an additional 28,406 shares during the period. 12.73% of the stock is owned by institutional investors and hedge funds.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.